Low or absent CXCR4 expression is predictive of a good response to sunitinib therapy, while CXCR4 expression is associated with a poor response to sunitinib in metastatic ccRCC (D’ Alterio et al., 2012). This evidence concerns the gene CXCR4 and nonpapillary renal cell carcinoma.